evaluation of CSF samples are inaccurate. Laboratory evaluation of the initial CSF sample revealed no eosinophils (not 3% eosinophils, as reported), and the diagnosis was made clinically, despite this finding. The second lumbar puncture showed 6% eosinophils (not 16% eosinophils, as reported) and was performed both in expectation of eosinophilia developing and in an attempt to help relieve the patient's headache.
Because a large number of people who arrive in Auckland are either migrants from the Pacific Islands or travelers returning from holidays spent in the Pacific Islands, where the disease is endemic, we are very familiar with eosinophilic meningitis due to A. cantonensis, and we see several cases per year. Indeed, 1 of the series of cases mentioned by Lo Re and Gluckman was evaluated and reported by our neurological colleagues at Auckland Hospital [2] . We do not, in general, find diagnosis of eosinophilic meningitis due to A. cantonensis to be "a major challenge," because the condition has a characteristic clinical symptomatology with an appropriate epidemiological history (even without the presence of CSF or peripheral blood eosinophilia, as initially was the case for the woman described by Lo Re and Gluckman [1] ) and is familiar to those of us in the fields of infectious diseases and neurology in this part of the world. Having said all that, we acknowledge that the ultimate proof of diagnosis was achieved by the Bangkok group mentioned in the article by Lo Re and Gluckman [1] .
Prolonged Candidemia in Patients with Cancer
Sir-We observed 4 cases of recurrent candidemia in patients with neoplastic disease who had central venous catheters. These cases were especially instructive because they were assessed both by antifungal susceptibility studies and by genotyping analysis performed using a randomly amplified polymorphic DNA (RAPD) technique described elsewhere [1, 2] .
Case patient 1 was a 47-year-old woman with a myelodysplastic syndrome who was neutropenic after receiving chemotherapy and who had 3 blood cultures that were positive for Candida glabrata (1 isolate was recovered on day 0 [the day that the first blood culture positive for Candida was performed], and 2 isolates were recovered on day 9) (table 1). Both susceptibility testing and RAPD analysis revealed that the isolate recovered from peripheral blood on day 0 was different from the isolates recovered from central venous catheter blood and peripheral blood on day 9 (figure 1). On day 22, a different urine isolate was identified by susceptibility testing, although it was genetically related to the initial yeast isolate (as determined by RAPD analysis). The patient died on day 23.
For case patient 2, the 3 Candida parapsilosis isolates recovered on day 0 and day 17 were found to be identical by use of both susceptibility testing and RAPD analysis; however, on day 30, a fourth isolate was identified as Candida dubliniensis (as confirmed by molecular analysis of the species-specific internal transcribed spacer region 2). An isolate recovered from the central venous catheter site after catheter removal was identical to the C. parapsilosis isolate recovered previously [3] . The patient survived. Two other patients with elevated peripheral blood leukocyte counts had multiple positive culture results. One patient had 4 blood cultures positive for C. albicans from day 0 to day 12, and another patient had 4 blood cultures positive for Candida lusitaniae from day 0 to day 18. The isolates from each patient were found to be identical by both susceptibility testing and RAPD analysis.
These case reports point out the difficulties associated with high-risk patients who have multiple blood cultures that are positive for Candida species. For case patient 1, susceptibility testing suggested 3 different strains, whereas RAPD analysis suggested only 2 different strains. Clinical management of such patients would be determined on the basis of the results of susceptibility studies in addition to evaluation of the clinical situation.
A different Candida isolate was recovered from case patient 2 on day 30, after the initial C. parapsilosis blood culture result was obtained. This patient survived, as did 2 additional patients, both of whom Figure 1 . Randomly amplified polymorphic DNA analysis of 3 bloodstream isolates and 1 urine isolate of Candida glabrata recovered from case patient 1. The 2 primers used were 5 -AAC GCG CAA C-3 and 5 -GAG GGT GGN GGN TCT-3 . Genetic relatedness among yeast isolates was determined by dendrogram analysis (Molecular Fingerprinting Plus software; Bio-Rad Laboratories). Band positions between 100 and 3000 bp (DNA molecularweight marker XIV; Roche Diagnostic) were computed using an area-sensitive similarity coefficient (S ab ) with 1.0 optimization. An S ab of 100 denotes identical strains, and an S ab of 0.0 denotes no match. C. glabrata isolates recovered from peripheral blood samples on day 0 and day 9 had an S ab of !83.3, or a 6-band disparity. An S ab of 75.9, or a 7-band difference in position, was noted for 2 isolates recovered on day 9. An S ab of 62.1, or an 11-band difference, was noted for isolates recovered from central venous catheter blood samples on day 0 and day 9, whereas the initial C. glabrata isolate recovered on day 0 and a urine yeast isolate recovered on day 22 had a high probability of genetic relatedness (S ab , 97.1 [1-band difference]). C-blood, central venous catheter blood; P-blood, peripheral blood.
had the same organism isolated 4 times during periods of 12 days (for C. albicans) and 18 days (for C. lusitaniae). Both patients survived, and C. lusitaniae remained susceptible to amphotericin B [4] .
We conclude that yeast isolates recovered from blood should be tested for susceptibility to commonly used antifungal agents just as bacteria are tested for susceptibility to antimicrobials. This report indicates that in highly susceptible granulocytopenic individuals, different strains and/or species may appear during prolonged episodes of hematogenous candidiasis. 
